TNF and Crohn disease: The SONIC (The Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease) and DIAMOND (Deep Remission of Immunomodulator and Adalimumab Combination Therapy for Crohn's Disease) studies investigated the efficacy of combined therapy with anti‐TNFα (infliximab, adalimumab) and IM, respectively, in patients with CD.38, 39, 40, 41, 42 Further studies are required to evaluate multiple options of combination therapies, including EBD, that would be suitable for individual patients to achieve mucosal healing to prevent intestinal complications and not only to promote remission.